Katholieke Universiteit te Leuven
Verified site
Leuven, Belgium
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study focuses on two rare sleep disorders, Narcolepsy and Idiopathic Hypersomnia. Both conditions cause excessive daytime sleepiness, meaning people feel very sleepy during normal waking hours, and can affect daily activities. The medication being tested is Xywav, a product that contains the active ingredient sodium oxybate along with related compounds. The purpose of the study is to evaluate the efficacy and safety of expanded dosing regimens of Xywav in adults with these disorders.
Participants first receive a stable dose of the medication for several weeks to allow the body to adjust. After this period, they are randomly assigned to continue receiving the study medication or to receive a placebo, a substance that looks the same but does not contain the active drug. Over the next few months, researchers track changes in daytime sleepiness using tools such as the Epworth Sleepiness Scale, a questionnaire where people rate how likely they are to fall asleep in different situations. They also monitor other symptoms, including sudden loss of muscle tone called cataplexy, and collect diary information about sleep patterns. Safety is checked by recording any side effects and routine health measurements.
The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.
14 criteria
24 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Leuven, Belgium
Namur, Belgium
Regensburg, Germany
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Narcolepsy is a chronic neurological disorder characterized by overwhelming daytime sleepiness and sudden episodes of muscle weakness (cataplexy) in many patients. It typically begins in adolescence or early adulthood and persists throughout life. The condition results from loss of neurons that produce the sleep‑regulating chemical orexin, causing unstable sleep‑wake boundaries. People with narcolepsy often enter rapid eye movement sleep quickly, leading to vivid dreams or hallucinations when falling asleep or waking. Symptoms may fluctuate in intensity, but the core features of sleepiness and cataplexy usually remain present over time.
Idiopathic hypersomnia is a long‑lasting sleep disorder marked by excessive daytime sleepiness that is not explained by other medical or sleep conditions. It usually starts in childhood or early adulthood and continues without a clear remission period. Affected individuals sleep for long durations at night and still feel unrefreshed, often struggling with prolonged sleep inertia after awakening. The excessive sleepiness can worsen with daily activities and may lead to frequent unplanned naps. While the severity can vary day to day, the underlying tendency toward persistent sleepiness remains stable.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.